Abstract: An RSV reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant RSV vector that contains an RSV genome encoding the disclosed RSV reporter strain operably linked to an expression control sequence. Also disclosed is an infectious RSV virion produce by expression of the disclosed recombinant RSV vector in a host cell. Also disclosed is a recombinant nucleic acid that comprises an RSV F protein having an escape mutation operably linked to a heterologous expression control sequence. Also disclosed are methods of screening for antiviral agents using the disclosed RSV reporter strains.

Abstract: A processor includes a transistor pair of a first transistor and a second transistor. The first transistor of the transistor pair is coupled to a Spaser and configured to output a drive current to the Spaser to pump the Spaser. Responsive to the drive current, the Spaser outputs surface plasmon polaritons (SPPs) which are fed to a plasmonic interconnect wire. The plasmonic interconnect wire propagates the SPPs. Further, the SPPs propagated on the plasmonic interconnect wire are detected by a phototransistor. Responsive to detecting the SPPs, the phototransistor generates an output current that is fed to a gate terminal of the second transistor to charge the second transistor.

Abstract: Disclosed are various embodiments for a parallel priority queue implemented on one or more many-core processors and/or multi-core processors such as those in general-purpose graphics processing units (GPGPUs). According to various embodiments, a priority may be determined according to a timestamp of an item, such as an event or an entry, in a priority queue. A priority queue interface may comprise functions to insert and remove entries from the priority queue. Priority order of the entries may be maintained as the entries are inserted and removed from the queue.

Abstract: Provided are methods and compositions for inhibiting or reducing fungal growth. The methods comprise exposing a location to a composition comprising one or more enzymes, one or more bacteria, and/or an enzymatic extract, wherein the one or more enzymes, one or more bacteria, and/or the enzymatic extract isolated from one or more bacteria are exposed to location in a quantity sufficient to inhibit or reduce fungal growth.

Abstract: Provided are methods and compositions for preventing or delaying a chill injury response of a plant or plant part that exhibits a chill injury response. The methods comprise exposing the plant or plant part to one or more bacteria, one or more enzymes, and/or an enzymatic extract isolated from one or more bacteria. The one or more bacteria, one or more enzymes, and/or the enzymatic extract isolated from one or more bacteria are exposed to the plant or plant part in a quantity sufficient to prevent or delay the chill injury response of the plant or plant part.

Abstract: Disclosed are methods, systems, and apparatuses for rapidly detecting a cellular interaction, such as ligand:receptor interactions. For example, the disclosed methods and systems can be used to detect a cellular interaction within 15 minutes to 75 minutes. This allows cells to be used as biosensors to detect cell activating agents in a sample.

Abstract: The present invention provides methods of forming hydrogen sulfide. The methods include contacting a precursor compound with an unmasking agent; wherein the precursor compound comprises a hydrogen sulfide releasing moiety and a masked nucleophile; and wherein the contacting is conducted under conditions sufficient for cyclization of the precursor compound via lactone or lactam formation; thereby releasing hydrogen sulfide from the precursor compound. Hydrogen sulfide precursor compounds according to Formula I are also described, as well as methods for treating diseases and conditions using hydrogen sulfide precursors.

Abstract: Inhibitors of SecA, and methods of making and using thereof, are described herein. The compounds described herein can be used to treat or prevent microbial infections, such as bacterial infections.

Abstract: Provided is a protein contrast agent for enhancing an MRI image and comprising a polypeptide having a conformation presenting at least five oxygen atoms positioned to chelate at least one paramagnetic metal ion such as Gd3+, each oxygen atom being between about 2 angstrom units and about 5 angstrom units from the metal ion; the metal ion has at least one water molecule electrostatically interacting a distance of less than about 10 angstrom units a target-specific moiety conjugated thereto, at least one polyethylene glycol molecule, and a paramagnetic metal ion. Also provided is a method of obtaining an enhanced MRI image using the protein contrast agent to a T2/T1 or T1/T2 intensity ratio of the MRI image; and (d) obtaining an image of the T2/T1 or T1/T2 intensity ratio.

Abstract: Disclosed herein are bactericidal compositions that are effective against pathogenic biofilms, especially against biofilms formed by Pseudomonas aeruginosa. The disclosed compositions comprise escapin intermediate products which can reduce the biofilm viability and biofilm matrix of P. aeruginosa.

Abstract: The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g.

Abstract: Disclosed are universal influenza A vaccines capable of providing broader crossprotection. The vaccine contains a fusion protein comprising tandem repeats of heterologous M2e epitope sequences that have been molecularly and genetically designed to provide broad cross-protection. The fusion protein may be incorporated into virus-like particles (VLPs) or a replicating live attenuated influenza virus vaccine, and administered alone or in combination with other influenza vaccines.

Abstract: Compounds having Formula I or II, and methods of making and using thereof, are described herein:

Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.

Abstract: Provided herein are heterocyclic near infrared compounds, including near IR compounds defined by Formulae I-V described herein. The near infrared compounds can include a cyanine group, a phthalocyanine group, a naphthalocyanine group, a squaraine group, a carbocyanine group, or a combination thereof. In some embodiments, the near infrared compound can be charged. In some embodiments, the near infrared compound can comprise a cationic group. Compositions comprising the near infrared compounds are also disclosed. In some embodiments, the composition can contain the near infrared compound, a polymer, and an acceptable carrier. In some embodiments, the polymer can include an anionic group. The compositions can be used as a coating for marking a surface, such as an ink. The compositions can also be used on articles for detecting, identifying, or authenticating the article. Methods of making the compositions described herein are also disclosed.

Abstract: The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.

Abstract: The present invention relates to compositions for and methods of optically imaging tissues or cells using imaging agents having desirable in vivo properties that result in improved signal-to-background ratio.

Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Abstract: Provided are methods and compositions for inhibiting or reducing fungal growth in or on a subject. The methods comprise exposing the subject to a composition comprising one or more enzymes, one or more bacteria, and/or an enzymatic extract, wherein the one or more enzymes, one or more bacteria, and/or the enzymatic extract isolated from one or more bacteria are exposed to the subject in a quantity sufficient to inhibit or reduce fungal growth.

Abstract: The present invention is directed to methods for inducing desired activity in enzymes or microorganisms capable of producing the enzymes. The invention is further directed to methods of stabilizing activity in microorganisms. In specific embodiments, the invention provides methods for inducing and stabilizing nitrile hydratase activity, amidase activity, and asparaginase I activity. The invention further provides compositions comprising enzymes or microorganisms having induced and/or stabilized activity.